Faravahar Heme-Onc Alliance (FHOA):

Uniting Persian Hematology & Oncology Professionals Worldwide

About Us

The Faravahar Heme-Onc Alliance (FHOA) is a global nonprofit organization dedicated to connecting Persian physicians, scientists, trainees, and healthcare leaders in the fields of hematology and oncology.

Founded on the principle that “our roots may be local, but our responsibility is global,” FHOA brings together professionals of Persian heritage across the world to foster:

Scientific collaboration and innovation in cancer and blood disorder research.
Educational mentorship for medical students, residents, and fellows.
Charitable outreach to underserved communities.
Cultural unity, celebrating Persian heritage within a global medical context.

By bridging science, culture, and compassion, FHOA strives to advance medicine, empower the next generation, and strengthen global collaboration among Persian medical professionals.

Our Services

Scientific Exchange

The Scientific Exchange Division of FHOA is dedicated to fostering collaboration across borders, empowering Persian physicians and scientists to work together on the frontiers of cancer medicine and hematology.

Charity & Outreach

At its core, the Faravahar Heme-Onc Alliance is not only about science — it is about service.

Culture & Heritage

Persian heritage is at the heart of the Faravahar Heme-Onc Alliance. The Faravahar symbol represents wisdom, progress, and unity — guiding values for our scientific and charitable mission.

Founder & Chair Of The Board

Founder of FHOA, hematologist, oncologist, and bone marrow transplant physician in San Antonio, Texas. Visionary behind the Alliance’s mission to unite Persian professionals worldwide.

Dr. Behyar Zoghi, MD, PhD, FACP

Founder Of FHOA

Join The Faravahar Heme-Onc Alliance

Membership in FHOA is open to all Persian and Persian-affiliated professionals in hematology and oncology.

Membership Levels

Member Benefits

Access To International Professional Networking
Mentorship And Career Development Opportunities
Participation In Research Collaborations
Invitations To Educational Events And Cultural Gatherings
Opportunity to contribute to humanitarian medical outreach

“whether You Are A Student Beginning Your Journey Or A Senior Physician Shaping The Field, The Faravahar Heme-onc Alliance Offers A Community Rooted In Persian Identity, Global Science, And Service.”

Latest Articles

Nonprofit Status: Application for 501(c)(3) recognition has been submitted, EIN obtained in the State of Texas.

Bylaws: The governing document of the Alliance, ensuring transparency, accountability, and alignment with the mission. Articles include:

The Faravahar Heme-onc Alliance (Fhoa) Is Structured As A Nonprofit, Charitable, And Educational Organization.

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.

Tumor-Infiltrating Clonal Hematopoiesis

Reveals that clonal hematopoiesis mutations within tumor microenvironments worsen outcomes — uniting hematology and solid tumor biology.

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

DLL3-targeted bispecific T-cell engager delivers the first real survival breakthrough in SCLC in decades — new benchmark for immuno-engagers.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

Transforms a historically lethal subset into a treatable disease with targeted triplet therapy; establishes new first-line standard.

Nonoperative Management of Mismatch Repair-Deficient Tumors

Immunotherapy replaces surgery for localized dMMR cancers — a paradigm shift proving organ preservation with 100% complete response rate.

How Close Are We to Achieving Durable and Efficacious Gene Therapy for Hemophilia A and B?

Extended follow-up of pegcetacoplan and new oral factor D inhibitors confirms near-complete hemolysis control with improved quality of life.

Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Long-term data showing sustained endogenous FVIII expression and reduced annualized bleed rates; establishes gene therapy as durable disease modification.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

First telomerase inhibitor to significantly improve transfusion independence in ESA-refractory MDS — now a frontline option before luspatercept failure.

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach

Prospective cohort demonstrating that targeted anti-inflammatory therapy in high-risk CHIP carriers reduces progression to AML/MDS. Bridges genomics, inflammation, and prevention.

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current review

Landmark long-term follow-up showing durable transfusion independence and reversal of vaso-occlusive crises with exa-cel and related CRISPR therapies — functional cures achieved.

A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma

Synthesizes 25 years of MSC trials; supports their safety and potential role in engraftment enhancement and immune modulation — a window into future graft engineering.

Mesenchymal stem cell infusion to accelerate hematopoietic recovery after transplantation: A comprehensive systematic review of clinical studies (2000–2025)

High-impact registry data showing comparable long-term outcomes in auto- vs allo-SCT; informs decision-making in lymphoid malignancies.

NCCN Clinical Practice Guidelines: Hematopoietic Cell Transplantation, Version 3.2025

Updated protocols for pre-HCT evaluation, GVHD prophylaxis, conditioning, and survivorship care. Core framework for quality and accreditation standards.

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

Recommendations Comprehensive update from EBMT harmonizing transplant indications with modern cellular and gene therapies. Essential reference for transplant program strategy and clinical justification.

Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR

Defines the new era of donor choice — prioritizing younger donors, clinical factors, and parallel donor searches rather than rigid HLA hierarchy. A practice-changing guideline for all transplant centers.

Recognized For Excellence In Patient Care.

I am honored to be recognized again as a Texas Super Doctor® for 2025, as published in Texas Monthly.

I am grateful for the continued recognition as a Texas Super Doctor since 2019, and to have been recognized nationally as a Castle Connolly Top Doctor since 2021.

These recognitions are meaningful to me because they reflect not a single moment, but a long-term commitment to caring for people facing serious and life-altering illnesses.

I have the privilege of working in bone marrow transplant, cellular therapies, and the care of patients with hematological malignancies—a field where science, teamwork, and humanity meet every day.

I am deeply grateful to my colleagues, multidisciplinary teams, and mentors—and most of all, to my patients and their families—for the trust they place in us during some of life’s most challenging moments.